Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




ImmunoGen’s Second License to Amgen (IMGN, AMGN)

Jyotsna Ramani (November 20th, 2009) Writes:

ImmunoGen, Inc. (NASDAQ:IMGN) has announced that Amgen, Inc. (NASDAQ:AMGN)Inc has licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology for the development of anticancer therapeutics to an undisclosed target. This is the second such license to be taken by Amgen – the company licensed the exclusive right to use ImmunoGen’s TAP technology for another undisclosed cancer target in September 2009.

Amgen Inc. is one of the leading biotechnology companies that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The Company markets human therapeutic products in the areas of supportive cancer care, nephrology and inflammation. While announcing the news, CEO and President of ImmunoGen Inc, Daniel Junius commented that the Company undertook extensive diligence prior to taking the first

...

CombinatoRx Neuromed Merger at risk? (NASDAQ:CRXX)

Jay Garcilazo (November 20th, 2009) Writes:

Neuromed and CombinatoRx, Incorporated (NASDAQ:CRXX)has agreed to sign a definitive merger agreement valued $28.8 million USD on 30th June, 2009 according to a news published by the RTT News.

Although the “merger” declaration with privately held Neuromeds Pharmaceutical Inc. did give a much required market boost, premarket trades for CombinatoRx Inc fell by 34 pct as reported by Reuters November 16th, 2009.

Regardless of the market fall for CombinatoRx, both companies are still sticking to the merger agreement and expected to close the transaction on 22nd November, 2009. Coincidentally, a pain killer drug “Exalgo” announced by Neuromed is in its current form not sufficient for approval under Section 505(b)(1) of the Food, Drug and Cosmetic Act of 1938, as amended (FDCA)

Exalgo, developed by ALZA Corp, is an “extended release” hydromorphone formulation, targeted for pain relief. U.S. marketing rights to this drug was sold

...

Sucampo Granted Marketing Authorization From FDA (NASDAQ:SCMP)

Jyotsna Ramani (November 20th, 2009) Writes:

Sucampo Pharma Europe Ltd, a subsidiary of Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) has announced that Swissmedic has granted a marketing authorization for Amitiza 24 mcg gel capsules for the long term treatment of patients with chronic idiopathic constipation (CIC). This decision by Swissmedic marks an important milestone in Sucampo’s global development and commercialization plan of lubiprostone for CIC, IBS-C and other indications. Amitiza is a local activator of type-2 chloride channels in cells lining the small intestine. It increases fluid secretion into the intestinal tract which softens the stool, facilitating intestinal motility and bowel movements. The type 2 chloride channels also play an important role in the restoration of tight junction complexes and in the recovery of barrier function in the body.

This marketing authorization is the first European regulatory approval for Sucampo and Amitiza is the first prescription medicine to

...

Power3 Investors Looking Forward to Expo (OTC:PWRM)

Jay Garcilazo (November 18th, 2009) Writes:

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the opening bell on heavy buying pressure. The spark which ignited the rise in share price is being speculated as being attributed due to the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 19-21, 2009, of which Power3 Medical will be attending. Excitement over the company is building, as they will now be exposed to over 50,000 scientists worldwide. Volume at the end of day was 21.62M as compared to the daily average of 2.6M.

About Power3 Medical Products, Inc.

Power3 Investors Looking Forward to Expo (OTC:PWRM)

Jay Garcilazo (November 18th, 2009) Writes:

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the opening bell on heavy buying pressure. The spark which ignited the rise in share price is being speculated as being attributed due to the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 19-21, 2009, of which Power3 Medical will be attending. Excitement over the company is building, as they will now be exposed to over 50,000 scientists worldwide. Volume at the end of day was 21.62M as compared to the daily average of 2.6M.

About Power3 Medical Products, Inc.

Exelixis PI3K Interim Data (NASDAQ:EXEL)

Jyotsna Ramani (November 18th, 2009) Writes:

Exelixis, Inc (NASDAQ:EXEL) has announced and reported that the interim data from an ongoing Phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid tumors have displayed positive results. XL147 is a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Exelixis has entered into a global license agreement with Sanofi-Aventis for XL147. Exelixis’ President of Research and Development, Michael M. Morrissey has mentioned that the preclinical data suggest that XL147 potentiates the antitumor efficacy of paclitaxel and carboplatin without exacerbating the toxicity of this commonly used regimen. Additionally, he also mentioned that they are very encouraged by this emerging signs of clinical activity and good tolerability of XL147 in combination with paclitaxel and carboplatin which will be used

...

ImmunoGen Announces IMGN901 Data (NASDAQ:IMGN)

Jyotsna Ramani (November 18th, 2009) Writes:

ImmunoGen, Inc (NASDAQ:IMGN) have reported the clinical data of their IMGN901 product candidate which will be used for the treatment of Merkel cell carcinoma (MCC). The Company mentioned that the meaningful evidence of anti-cancer activity has been noted in limited number of patients who are suffering from MCC and who have received IMGN901. The findings were reported at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, MA, and suggest development for metastatic MCC could be a potential registration path for IMGN901. MCC is an aggressive neuroendocrine cancer of the skin that typically occurs on the head or neck, most often in individuals of European ancestry. However, each year there are about 1400 cases of MCC diagnosed in the United States each year and the trend for MCC is increasing every year.

...

Bullish Technical Breakout Alert (OTC:SNBP)

Jay Garcilazo (November 17th, 2009) Writes:

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/17/09 on Sinobiopharma Inc (OTC:SNBP) Inc. has initiated an independent bullish technical trading alert for 11/17/09 on Sinobiopharma, Inc. (OTC:SNBP.OB). Shares of the company finished the day at $0.25, up 38.89% from the opening bell on heavy buying pressure. The turning point in the share price which had been experiencing a down trend for well over a year, resulted from record volume totalling 2,911,677 which trumped the volume average of 265,000.

Investors have begun to feel a renewed sense of optimism towards the company on the eve of their recent press release. Sinobiopharma announced that 23 generic drugs for which the Company has production rights are listed in China’s National Essential Drugs

...

ArQule’s Drug Discovery Platform (NASDAQ:ARQL)

Jyotsna Ramani (November 17th, 2009) Writes:

ArQule Inc (NASDAQ:ARQL) has presented their data at the AACR-NCI-EORTC meeting in Boston which clearly demonstrates the capabilities of Company’s proprietary drug discovery platform to generate a class of small molecules that has significant therapeutic potential. The data reflected the results of the application of the ArQule Kinase Inhibitor Platform (AKIP) to discover and optimize a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR) that are not ATP-competitive and that show potent anti-tumor activity in FGFR-driven cancer models.

ArQule is a biotechnology company which looks after the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™)

...

Enzo Biochem Ready to Reveal EGS21 Data (NYSE:ENZ)

Jay Garcilazo (November 17th, 2009) Writes:

Enzo Biochem Inc (NYSE:ENZ) has announced that their Vice President of Corporate Development, David Goldberg will speak about Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 Conference which will be held in Boston on Wednesday, November 18, 2009. The Company announced that Enzo Biochem’s EGS21, an orally administered beta glucosylceramide formulation, which is currently undergoing clinical study, has been named one of this year’s top 10 inflammatory and autoimmune projects to watch. The TA Partnership Conference is sponsored by Windhover Information Inc which is world’s leading publisher of science, technical and health information.

Enzo Biochem have already presented their EGS21 clinical studies data recently at the Liver Conference where they showed that the oral administration of EGS21 is safe and appears to be biologically active in patients

...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.